Solid oral dosage form medications identified by all three pharmacists to have been inappropriate for modification
| Medications | No. of patients, (%) (n=50) |
| Modified-release products | |
| Gliclazide MR 60 mg tablet | 1 (2) |
| Sodium valproate 300 mg or 500 mg chrono tablets | 2 (4) |
| Products that may cause gastrointestinal tract irritation | |
| Alendronate 70 mg tablet | 1 (2) |
| Dutasteride/ tamsulosin 0.5 mg/0.4 mg capsule | 1 (2) |
| Risedronate 35 mg tablet | 1 (2) |
| Products with potential cytotoxic or teratogenic effect | |
| Letrozole 2.5 mg tablet | 1 (2) |
| Methotrexate 2.5 mg tablet | 1 (2) |
| Total | 8 (16) |